8.30 USD
▲+0.32+6.14%
盘后 7.86 +0.51%
2026-08-03
市值
$371.44M
市盈率
4.29
EPS
1.93
股息率
—
52 周区间
2.71 – 8.70
成交量
2.02M
Beta
1.55
目标价
30.00
52W 低 2.7152W 高 8.70
价格走势
公司简介
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ...